Our Mission
Transform how the immune system targets and fights disease by developing a new generation of targeted cancer treatments.
About PDS Biotech
PDS Biotech was established with the goal of harnessing the power of T cells to address some of the most devastating illnesses of our time. While many companies have tried to leverage the body’s own immune system to induce a powerful T cell response, most have been unsuccessful in overcoming the tumor’s ability to protect itself against the immune system and also inducing the right type and quantity of potent tumor-infiltrating T cells to execute a targeted attack. Our proprietary targeted technologies are designed to deliver IL-12 into the tumor’s inner environment to suppress the tumor’s ability to protect against T cells while simultaneously generating a potent targeted T cell attack on the cancer.
When paired with proprietary tumor-associated proteins called antigens, Versamune® has been shown to promote the induction of the right type and quantity of potent tumor-infiltrating killer and helper T cells, that specifically recognize the tumor antigen. PDS01ADC, our novel investigational tumor-targeting IL-12 fused antibody drug conjugate, when used with Versamune®, overcomes tumor-induced suppression of the immune system. The proprietary combination also promotes enhanced infiltration and expansion of the T cells within the tumor, leading to more effective immunotherapy. Our Infectimune® platform is being used in the development of novel investigational T cell and antibody inducing preventive vaccines.
PDS Biotech is committed to developing novel investigational immunotherapies based on our T cell stimulating platforms to save and improve the lives of patients worldwide:
- Versamune® based T-cell Stimulating Immunotherapies (TSI) to provide a targeted attack against tumor-associated proteins called antigens
- Versamune® based T-cell Stimulating Immunotherapy (TSI) plus PDS01ADC, our novel investigational tumor-targeting IL-12 fused antibody drug conjugate, targets the tumor microenvironment to suppress the tumor’s protections against the immune system, and also promotes enhanced infiltration and expansion of the T cells within the tumor to treat recurrent and/or metastatic (R/M) cancers with poor survival prognosis
